Gongwin
共信醫藥科技控股股份有限公司
Gongwin is a Taiwan TPEx-listed biotechnology company; its most advanced asset is PTS100 (Phase 2 enrollment completed; efficacy evaluation ongoing, Liver cancer not suitable for surgery or after failed local treatment), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| PTS100 | — | Phase 2 enrollment completed; efficacy evaluation ongoing | Liver cancer not suitable for surgery or after failed local treatment | Taiwan | 2026-06-05 | Company disclosure |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.